Fezolinetant (Veozah): The Definitive Guide

What is fezolinetant?

Fezolinetant is a prescription nonhormonal medicine for moderate to severe hot flashes and night sweats associated with menopause. The US brand is Veozah; the UK product is Veoza. It blocks the neurokinin 3, or NK3, receptor involved in the brain’s temperature regulation. It contains neither estrogen nor a progestogen and does not restore an estrogen blood level. [1], [2]

Its purpose is specific symptom relief. It is not a treatment for every menopause problem, a contraceptive, or an estrogen substitute for bone or vaginal-tissue goals. Someone can have fewer hot flashes and still need assessment of painful sex, persistent insomnia, mood symptoms or bone health. The broader nonhormonal treatment guide explains how the choices fit different problems. [1], [2], [8]

The practical commitment includes one daily tablet and liver testing. Serious liver injury has been reported after marketing; the current US label carries a boxed warning. Being nonhormonal does not make laboratory follow-up optional. Before starting, confirm the actual product, interacting medicines and how the required tests will be arranged. [1], [2], [5]

What are the labeled fezolinetant schedules?

The labeled pattern is daily continuous use of one whole 45 mg tablet, with or without food. The reviewed labels do not provide a higher-dose symptom-titration ladder. The amount is tablet content, not a patch rate or hormone-equivalence calculation. Baseline suitability and testing come before treatment, and long-term benefit is reviewed periodically. Missed-dose and stop instructions remain product-specific. [1], [2]

What can improve, and what needs another plan?

The main evidence concerns the frequency and severity of moderate to severe vasomotor symptoms. A useful treatment goal might be fewer disruptive episodes at work or fewer sweat-related awakenings, rather than expecting every symptom to disappear. Record what interfered with your day before starting; that makes partial improvement easier to discuss than an overall judgement that menopause is better or worse. [1], [6]

Sleep can improve when vasomotor symptoms improve. In DAYLIGHT, participants reported less sleep disturbance than the placebo group at 24 weeks. That questionnaire result is not proof that fezolinetant treats every insomnia disorder. Insomnia is also a listed adverse reaction. Continuing difficulty sleeping needs assessment of its actual causes, including whether night sweats have changed. [1], [2], [6]

Dryness, painful sex and urinary symptoms belong to a different treatment discussion. Fezolinetant does not supply local estrogen or regenerate vaginal tissue by its hot-flash mechanism. The UK SmPC’s caution against adding systemic estrogen HRT explicitly excludes local vaginal preparations. This distinction allows a product-specific discussion without assuming that every hormonal preparation has the same interaction or purpose. [2]

The treatment can be considered when menopausal HRT is unsuitable or someone prefers a nonhormonal option, after evaluating their history. In England, NICE’s funding recommendation specifically covers the HRT-unsuitable population; that is narrower than the product license. A personal preference, contraindication and reimbursement eligibility are related questions but not interchangeable definitions. [2], [3], [6]

How does it affect temperature regulation?

The hypothalamus is a brain region involved in temperature regulation. Menopause-related estrogen decline changes signaling in a group of neurons commonly called KNDy neurons. Neurokinin B acting at NK3 receptors is part of that signaling. Fezolinetant blocks this receptor rather than adding estrogen. The explanation is a simplified mechanism, not a brain scan demonstrating that a person’s thermostat has been repaired. [1], [2]

This helps explain why a nonhormonal medicine can relieve a symptom associated with estrogen decline. It does not imply that a hormone concentration has normalized or that all estrogen-dependent tissues are treated. The UK SmPC reports no clear clinically relevant change in measured sex hormones during treatment. A hot-flash response is therefore not a test of estrogen sufficiency, bone protection or fertility. [2]

Fezolinetant and elinzanetant are different molecules. The former selectively antagonizes NK3; the latter has a dual NK1/NK3 mechanism. Their capsule/tablet amounts and follow-up instructions are not interchangeable. A mechanism comparison alone cannot establish which will produce better sleep or fewer unwanted effects in a particular person. Read the elinzanetant guide with its own label and evidence. [1], [2], [8]

How large was the benefit in controlled trials?

The US label describes two initial 12-week randomized placebo-controlled trials. Across both, 1,022 postmenopausal women were assigned to one of two fezolinetant amounts or placebo; that total is not the number who all received the approved 45 mg amount. Participants had at least seven moderate/severe episodes daily on average. Prior HRT users underwent a washout. These studies do not establish the benefit of adding fezolinetant to an ongoing systemic estrogen regimen. [1]

At week 12, trial 1 showed adjusted reductions of 6.4 daily episodes with 45 mg and 3.9 with placebo; trial 2 showed reductions of 7.5 and 5.0. The reported adjusted drug-placebo differences were 2.6 and 2.5 fewer episodes daily. These are group estimates from statistical models, not a promise of that exact improvement. Both placebo groups improved substantially, so citing only change from baseline exaggerates the comparative benefit. [1]

DAYLIGHT answered a related question in 453 people aged 40–65 considered unsuitable for hormone therapy. Categories included contraindication, caution, previous stopping and informed preference against hormone therapy. Fezolinetant 45 mg was compared with placebo for 24 weeks. The adjusted frequency difference at week 24 was 1.93 fewer daily moderate/severe episodes, with a 95% confidence interval from 1.22 to 2.64 fewer. Most participants were White and many were in caution or preference categories. It was not a trial proving safety during every cancer treatment. [6]

Trial duration matters. Initial efficacy comparisons were 12 weeks; extensions and safety studies provided longer follow-up. Endometrial observations in the label included isolated hyperplasia and malignancy findings. Their presence does not establish causation, and their rarity does not prove zero future cancer risk. Fezolinetant is not an endometrial-protection substitute when someone separately receives systemic estrogen. New unexplained bleeding still needs assessment. [1], [8]

NICE says fezolinetant has not been directly compared with other nonhormonal treatments in its assessment. Indirect comparisons are uncertain. Separate placebo-controlled studies cannot support a reliable head-to-head ranking against elinzanetant, paroxetine or gabapentin, particularly when baseline symptom burden, populations, endpoints and follow-up differ. [3]

Which adverse effects need prompt action?

New unusual fatigue, poor appetite, nausea or vomiting, itching, yellow skin/eyes, pale stools, dark urine or abdominal pain can suggest liver injury. The US label tells patients to stop Veozah immediately and seek medical attention, including liver tests, if these occur. Do not wait for the next planned test or assume that fewer hot flashes proves the liver is healthy. A symptom diary supports the history; it cannot decide whether the medicine is safe to continue. [1], [5]

The US trials reported ALT/AST above three times the laboratory upper limit in 2.3% receiving Veozah and 0.9% receiving placebo across three trials. These proportions differ from exposure-adjusted rates and must not be mixed. Postmarketing serious injury included cases within 40 days of starting. Spontaneous reports cannot provide a dependable individual frequency, but they changed the precautions. [1], [5]

Abdominal discomfort, diarrhea, insomnia and other effects can affect whether treatment is useful. Persistent or disruptive effects deserve review even when they do not fit liver-warning symptoms. Conversely, a mild symptom label such as nausea must not lead someone to ignore a new cluster suggesting liver injury. The timing, severity, associated symptoms and actual medicines help the clinician distinguish possibilities. [1], [2]

US contraindications include known cirrhosis, severe renal impairment or end-stage renal disease, and CYP1A2 inhibitors. The UK product words its liver/kidney restrictions differently and contraindicates moderate/strong CYP1A2 inhibitors. Do not merge these into a universal rule that weak inhibitors are always acceptable or that absence of cirrhosis makes every liver condition safe. The actual local product label governs the medication review. [1], [2]

The UK SmPC does not recommend use during ongoing oncologic treatment for breast cancer or other estrogen-dependent malignancies because these patients were not included in the studies. After completed cancer treatment, it calls for individual benefit/risk consideration. A nonhormonal mechanism does not establish safety in every oncology history; coordinate the decision with the relevant team. [2]

What belongs in the medication review?

CYP1A2 is an enzyme involved in fezolinetant breakdown. An inhibitor can increase medicine exposure even when the second product is taken for an unrelated problem. Bring prescription medicines, over-the-counter products and supplements to the pharmacist’s review. The US label includes weak, moderate and strong inhibitors in its contraindication; UK rules identify moderate/strong inhibitors. Lists in a general guide cannot replace checking the actual products. [1], [2]

Do not add systemic estrogen simply because hot flashes are only partially controlled. The UK SmPC says concomitant estrogen HRT has not been studied and is not recommended, while excluding local vaginal preparations. If systemic HRT is being changed or stopped, its progestogen/protection and symptom plan need their own review. Fezolinetant cannot quietly replace one hormonal component. [2], [8]

Pregnancy and contraception remain separate questions during perimenopause. The UK product is contraindicated in known or suspected pregnancy and advises effective contraception, preferably nonhormonal in its product information. Hot flashes and irregular periods alone do not prove pregnancy is impossible. Ask about the actual contraceptive product too, because some estrogen-containing contraceptives are relevant CYP1A2 inhibitors. [2]

What if a tablet is missed?

The reviewed US and UK labels say to take a missed dose when remembered unless fewer than 12 hours remain before the next scheduled dose, then return to the usual schedule the following day. This is the product’s missed-dose rule, not a reason to take extra tablets for a breakthrough hot flash. Do not cut, crush or chew the tablet to improvise smaller amounts. [1], [2]

A refill interruption, an intentionally withheld dose and a missed liver appointment are different events. Record the actual last tablet and contact the team when testing or supply cannot be arranged. The guide does not supply a restart algorithm after suspected liver injury or authorize continuing without scheduled tests. New symptoms during a gap still need assessment of their cause. [1], [2], [5]

How should the product and records be kept?

The US product label gives storage at 20–25°C, with permitted excursions to 15–30°C. The UK SmPC says no special storage conditions are required. These are product-specific packaging instructions, not a reason to store tablets in a hot car or ignore the dispensed pack’s expiry. Keep the medicine identifiable and away from children. [1], [2]

Keep the product name and 45 mg tablet strength with the start date, medication review and laboratory appointments. The symptom log should distinguish hot-flash burden from new unwanted symptoms. The actual laboratory report and clinician’s interpretation remain necessary; a calendar tick or a normal-feeling day is not a liver result. [1], [2]

Access can affect continuity. Health Canada’s reviewed rationale establishes authorization, while NICE TA1143 establishes a particular England funding recommendation. Neither proves a pharmacy has stock or that an individual insurer covers the prescription and laboratory costs. Confirm those practical arrangements before starting and before travel or a change of care team. [3], [4], [7]

What do public accounts help explain?

A 2026 public discussion includes accounts of fewer hot flashes and better sleep, alongside reports that symptoms later returned. Other participants are still deciding whether to start. Those accounts show why follow-up should record early benefit and whether it persists; they do not establish a typical time to response or the probability that benefit will wear off. [9]

Another public thread asks about continuing severe symptoms and adding supplements when estrogen is not an option. It shows a need for a broader symptom plan and a medication/supplement review. Forum assurances about combinations or cancer suitability are not clinical evidence. Continuing symptoms, absent benefit and unwanted effects deserve the same visibility as positive accounts. [10]

Coverage and copay questions also appear. A selected person’s insurance outcome cannot establish today’s price for another plan or country. Keep public experiences separate from regulator and trial evidence, and bring the practical questions to the prescriber or pharmacist. No usernames, satisfaction scores or representative survey are reported here. [9], [10]

What should be monitored?

Before starting US Veozah, the label requires ALT, AST, alkaline phosphatase and total/direct bilirubin. Do not start if ALT or AST is at least twice the laboratory upper limit or total bilirubin is at least twice that limit. These are clinician-interpreted safety thresholds, not targets to self-manage. Review relevant liver and kidney disease and medicines at the same time. [1]

US follow-up testing is monthly during the first three months, then at months six and nine. UK Veoza also requires baseline and monthly first-three-month tests, then further testing based on clinical judgement. Both need testing when signs suggest injury. Arrange the calendar before the first tablet and contact the team when an appointment, result or refill is delayed. A scheduled month does not postpone urgent assessment. [1], [2], [5]

The US label requires discontinuation if transaminases exceed five times the upper limit, or exceed three times together with total bilirubin above twice the limit. Above-three-times transaminases prompt more frequent tests until resolution. UK instructions additionally name elevations at least three times with liver-injury symptoms as a stop situation. Keep exact inequalities and the local product attached to the decision. [1], [2]

Follow-up also asks whether hot flashes, sleep disruption and daily function have meaningfully improved, whether adverse effects remain acceptable and whether treatment is still needed. No estrogen or progesterone blood target measures success with this medicine. Bring actual use dates, missed tablets, symptom notes and new medicines, while retaining the laboratory reports and clinician’s interpretation. [1], [2], [6]

What happens when treatment stops?

Suspected liver injury is an immediate-stop situation in the US instructions, followed by medical assessment. It is not a gradual taper to finish a bottle. The guide does not authorize restarting after an abnormal result or suspected injury; the prescriber must evaluate the cause, recovery and product restrictions. Keep the last actual dose and symptom onset available. [1], [2], [5]

For a planned change because benefit is insufficient, unwanted effects or access problems, discuss the next symptom-management plan. The reviewed labels do not provide a universal tablet-cutting taper. Hot flashes may still require treatment after stopping, and a different nonhormonal medicine has its own contraindications, start rules and follow-up. A forum report of stopping and restarting is not a validated personal strategy. [1], [2], [9]

Stopping fezolinetant does not automatically stop separate vaginal treatment, systemic HRT or endometrial protection. If another medicine continues or changes, its purpose and safety plan remain visible. This is especially useful when care is transferred: list what stopped, what continued and why, rather than recording only that menopause medication changed. [2], [8]

How does it compare with other options?

The 2023 NAMS position statement recommends several evidence-supported nonhormonal options, including fezolinetant, selected SSRIs/SNRIs, gabapentin and behavioral approaches. It predates elinzanetant approval and the later liver-warning changes. Current product labels therefore add information the older guideline cannot supply. NICE’s narrower funding recommendations belong to their own health-system context. [3], [8]

A comparison should begin with the symptom and practical burden: daily dosing, liver appointments, sedation, interacting medicines, psychiatric treatment needs and access. Paroxetine’s specific hot-flash product is not a substitute for indicated psychiatric care; gabapentin and elinzanetant have different adverse-effect and interaction profiles. None should be chosen by comparing their milligram numbers with 45 mg fezolinetant. [1], [8]

Hormonal treatment may address different goals when suitable, but fezolinetant does not automatically replace estrogen’s other purposes. Local vaginal therapy is a separate route-specific question. The evidence does not permit a universal claim that one nonhormonal product is most effective or safest for everyone. Read each product’s guide, and assess benefit against its own placebo comparison and current precautions. [1], [2], [3], [8]

Common questions

Is it estrogen or an antidepressant?

Neither. Fezolinetant is a nonhormonal NK3 receptor antagonist for menopause-associated hot flashes/night sweats. It does not replace estrogen for every tissue or goal. Paroxetine belongs to a different drug class. A medicine’s place in a menopause library does not make every item HRT. See the explanation. [1], [2] Keep the actual symptom goal visible when reviewing benefit. A different medicine may address a different problem and carry a different testing requirement. See the clinical purpose. [1] [2]

Which liver-test calendar applies?

US Veozah requires baseline tests, monthly testing in months 1–3 and tests at months 6 and 9. UK Veoza requires baseline and monthly first-three-month testing, then clinical judgement. Symptoms can require unscheduled tests at any time. Follow the actual local prescription, not another neurokinin drug’s calendar. See monitoring. [1], [2] A symptom-triggered test can be needed before any scheduled visit. Record the start date and actual test results, not only a reminder that a test was due. See the monitoring plan. [1] [2]

Can I skip testing if I feel well?

No. Trial enzyme elevations were often asymptomatic, and the current label requires planned testing. Feeling well or having fewer hot flashes is not proof of normal liver results. If testing cannot be arranged, contact the prescribing team about the treatment plan. The guide cannot approve a testing gap. [1], [2], [5] Discuss feasibility before the first tablet so the laboratory plan is concrete. Absence of symptoms cannot substitute for the required biochemical assessment. See the safety precautions. [1] [2]

Can I add it to my estrogen patch?

The UK SmPC says concomitant systemic estrogen HRT has not been studied and is not recommended; local vaginal preparations are excluded from that caution. Do not add or remove a component yourself. The entire regimen and uterine-protection question need review. See interactions. [2], [8] Local vaginal treatment is not the same as systemic estrogen exposure. Clarify each product with the prescriber and pharmacist before making a combined-treatment decision. See the medication interactions. [2] [8]

Is it proven safe during breast-cancer treatment?

No universal claim is justified. UK Veoza does not recommend use during ongoing oncologic treatment because the relevant population was not included. DAYLIGHT’s HRT-unsuitable population is not proof of every cancer combination. Discuss the actual treatment with the oncology team. [2], [6] A study population described as HRT unsuitable includes more than one reason for that designation. The person’s cancer medicine and stage of care remain important. See the treatment goals. [2] [6]

Can I take a second tablet for breakthrough symptoms?

The reviewed approved amount is one 45 mg tablet daily, not an as-needed rescue treatment or self-titration ladder. A missed-dose rule is different from an extra dose. Review adherence, interactions, benefit and alternatives with the prescriber if symptoms remain disruptive. See protocols. [1], [2] An increase should not be improvised from another product’s amount. Bring the actual use, symptom burden and complete medicine list to reassessment. See the product schedules. [1] [2]

Does this mean I can stop all my other menopause treatments?

No. Hot-flash treatment, vaginal symptoms, bone health and protection during systemic estrogen are separate goals. The current treatment plan may change, but fewer hot flashes alone does not settle each question. Bring the complete prescription and treatment goals to review. See comparisons. [1], [2], [8] A complete review can distinguish which problems improved and which need their own care. Another treatment may have a purpose beyond reducing vasomotor episodes. See the treatment comparisons. [1] [2]

Glossary

Terms used to read the product and evidence.

ALT

A liver-related enzyme measured in blood; an elevation needs clinical interpretation.

AST

An enzyme measured with other liver tests; it is not a symptom score.

Alkaline phosphatase

A blood-test enzyme used with other findings to assess liver or biliary problems.

Antagonist

A substance that blocks activity at a particular receptor.

Baseline

A measurement recorded before treatment begins.

Bilirubin

A pigment measured in blood; its elevation can accompany liver or biliary disease.

Boxed warning

A prominent US label warning about a serious risk.

CYP enzyme

An enzyme involved in medicine metabolism; inhibitors and inducers may alter exposure.

Cirrhosis

Advanced liver scarring; product restrictions may specifically name it.

Contraindication

A circumstance in which a product label says the medicine must not be used.

Drug-induced liver injury

Liver injury attributed to a medicine after assessment of other possible causes.

Endocrine therapy

Treatment affecting hormone production or action; cancer endocrine therapy is distinct from menopausal HRT.

Estrogen

A hormone used in some menopause treatments; these nonhormonal medicines do not replace it.

Hot flash

An episode of heat, often with flushing or sweating.

Hypothalamus

A brain region involved in temperature regulation and other bodily functions.

Inducer

A substance that increases enzyme activity, potentially reducing exposure to another medicine.

Inhibitor

A substance that reduces enzyme activity, potentially increasing exposure to another medicine.

Jaundice

Yellowing of skin or the whites of the eyes that needs assessment.

Least-squares mean

A model-adjusted average used in trial analyses, distinct from a simple raw average.

Median

The middle value in ordered data, different from the arithmetic mean.

Neurokinin receptor

A receptor responding to neurokinin signals; a drug may block a specified subtype.

Night sweat

Sweating episodes during sleep; a vasomotor episode is one possible cause.

Nonhormonal

A treatment that does not supply estrogen or progestogen; the term does not mean risk-free.

Off-label

Use outside the authorization for the exact product and jurisdiction.

Placebo

A comparison treatment without the trial medicine; its group can still improve.

Progestogen

A hormone-family treatment used for endometrial protection in many systemic estrogen regimens.

Randomized trial

A study assigning treatment groups by chance to help compare outcomes.

SSRI

A selective serotonin reuptake inhibitor; some specific products or amounts are used for hot flashes.

Serotonin

A chemical messenger affected by SSRIs and relevant to their interactions.

Tamoxifen

An endocrine medicine used in breast-cancer care; interacting treatments need review.

Upper limit of normal

The upper reference limit provided by the evaluating laboratory.

Vasomotor symptoms

Hot flashes and night sweats associated with menopause or a specifically assessed other cause.

How this guide was researched

We reviewed the full current US and UK labels, the MHRA liver-safety communication, final NICE recommendation and overview, the full original DAYLIGHT report, Canadian approval rationale and the 2023 NAMS statement. Protocol rows use complete product information with revision dates. Trial estimates retain population, comparator and duration; approval, funding and live supply remain separate. The older Canadian approval rationale is not described as a fresh 2026 monograph. [1]–[8]

The public-source directory identifies selected thread text retrieved through search. These accounts support reader questions rather than satisfaction rates, expected response times or cancer suitability. We did not access private content. Mechanism and calendar figures are conceptual/educational, with exact source-bound values.

Checked 2 October 2026.

Explore the sources